Given Imaging gets Bravo from Medtronic
This article was originally published in The Gray Sheet
Executive Summary
Given Imaging acquires Medtronic's Bravo wireless gastroesophageal reflux disease monitor business for $20 million Dec. 8. The catheter-free GERD test, which uses a disposable capsule temporarily placed in the esophagus to measure pH levels and transmit data to an external receiver, will add about $12 million to Given's sales in 2009, the firm predicts. Bravo "is a synergistic and strategic fit" with Given's PillCam video capsule-based diagnostic system for gastrointestinal disorders, according to the company
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.